Hirntumortherapie

Zusammenfassung

Die Therapie der primären Hirntumoren erfährt derzeit einen neuen Schub durch dia-gnostisch und therapeutisch relevante Erkenntnisse im molekularen Bereich. Es werden Defekte der Wachstumsregulation definiert, die in ähnlicher Form auch bei anderen malignen Erkrankungen vorkommen. Gegen diese definierten Defekte werden immer mehr zielgerichtete Therapien mit spezifischen Hemmstoffen verfügbar. Dadurch eröffnen sich neue Perspektiven, die Therapie zu verbessern.

Summary

Therapy of primary brain tumours gets a new impact by new insights into the molecular mechanisms of disturbed cell growth. It is possible, to define specific defects of cellular signal transduction cascades, which often use similar in other malignant tumours. Thus specific inhibitors available for other tumours may also be applied in gliomas providing new therapeutic options.

Schlüsselwörter

Gliome - Chemotherapie - molekulare Diagnostik - zielgerichtete Therapie

Keywords

Glioma - chemotherapy - molecular diagnostic - targeted therapy

• Literatur

• 1 Barnholtz-Sloan JS. et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveil-lance System. J Clin Oncol 2004; 22: 2865-72.
• 2 Braus DF. et al. Primary cerebral malignant nonHodgkin‘s lymphomas: a retrospective clinical study. J Neurol 1992; 239: 17-24.
• 3 Cloughesy TF. et al. A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). J Clin Oncol (Meeting Abstracts) 2008; 26: 2010.
• 4 Delattre JY. et al. Distribution of brain metastases. Arch Neurol 1988; 45: 741-4.
• 5 Hegi ME. et al. MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma. N Engl J Med 2005; 352: 997-1003.
• 6 Mohile NA, Abrey LE. Primary central nervous system lymphoma. Neurol Clin 2007; 25: 1193-207.
• 7 Sanai N, varez-Buylla A, Berger MS. Neural Stem Cells and the Origin of Gliomas. N Engl J Med 2005; 353: 811-22.
• 8 Stupp R. et al. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. N Engl J Med 2005; 352: 987-96.
• 9 Vredenburgh JJ. et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007; 25 (Suppl. 30) 4722-9.
• 10 Walker MD. et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 1978; 49: 333-43.
• 11 Weil RJ. Incorporating Molecular Tools into Early-Stage Clinical Trials. PLoS Med 2008; 5: e21.
• 12 Wen PY, Kesari S. Malignant Gliomas in Adults. N Engl J Med 2008; 359: 492-507.
• 13 Yan H. et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360 (Suppl. 08) 765-73.